• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Isolation of Antimicrobial Compounds From Cnestis ferruginea Vahl ex. DC (Connaraceae) Leaves Through Bioassay-Guided Fractionation
Conclusion In conclusion, aqueous extracts of C. ferruginea leaves showed antimicrobial activity due to the presence of hydroquinone and caffeic acid methyl ester. This supports its traditional use for infections and confirmed that the active molecules are water-soluble. Author Contributions KK, SP, LVP, and WL conceived and designed the experiments. SP, KK, M-RY, and J-GL performed the experiments. SP, LVP, WL, M-RY, J-GL, and Z-HJ analyzed the data. WL and Z-HJ contributed reagents, materials, and analysis tools. KK, SP, WL, M-RY, Z-HJ, and LVP contributed to the writing of the manuscript. All authors contributed to m...
Source: Frontiers in Microbiology - April 10, 2019 Category: Microbiology Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news